Free Trial
NASDAQ:IMMX

Immix Biopharma (IMMX) Stock Price, News & Analysis

Immix Biopharma logo
$2.19 -0.09 (-3.95%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.18 0.00 (-0.23%)
As of 08/22/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Immix Biopharma Stock (NASDAQ:IMMX)

Key Stats

Today's Range
$2.17
$2.32
50-Day Range
$2.07
$2.99
52-Week Range
$1.26
$3.20
Volume
175,020 shs
Average Volume
254,769 shs
Market Capitalization
$63.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Immix Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

IMMX MarketRank™: 

Immix Biopharma scored higher than 62% of companies evaluated by MarketBeat, and ranked 358th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immix Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immix Biopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Immix Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Immix Biopharma are expected to grow in the coming year, from ($0.87) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immix Biopharma is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immix Biopharma is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immix Biopharma has a P/B Ratio of 13.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immix Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    1.18% of the float of Immix Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Immix Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immix Biopharma has recently decreased by 14.76%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Immix Biopharma does not currently pay a dividend.

  • Dividend Growth

    Immix Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.18% of the float of Immix Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Immix Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immix Biopharma has recently decreased by 14.76%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for IMMX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immix Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,061.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    55.40% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.26% of the stock of Immix Biopharma is held by institutions.

  • Read more about Immix Biopharma's insider trading history.
Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

IMMX Stock News Headlines

Immix Biopharma Announces Other Serious Diseases Strategy
When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.tc pixel
Immix Biopharma Attends FDA CEO Forum in Washington DC
See More Headlines

IMMX Stock Analysis - Frequently Asked Questions

Immix Biopharma's stock was trading at $2.20 at the beginning of the year. Since then, IMMX shares have decreased by 0.5% and is now trading at $2.19.

Immix Biopharma, Inc. (NASDAQ:IMMX) announced its earnings results on Friday, August, 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.01.

Immix Biopharma (IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share.

Immix Biopharma's top institutional shareholders include Velan Capital Investment Management LP (0.09%) and Tritonpoint Wealth LLC (0.09%). Insiders that own company stock include Ilya M Rachman, Jason Hsu, Gabriel S Morris, Carey Ng, Helen C Adams and Magda Marquet.
View institutional ownership trends
.

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

Last Earnings
8/08/2025
Today
8/23/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMMX
CIK
1873835
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$7.00
Potential Upside/Downside
+219.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.61 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-205.35%
Return on Assets
-110.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.23
Quick Ratio
1.23

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.16 per share
Price / Book
13.69

Miscellaneous

Outstanding Shares
28,830,000
Free Float
12,860,000
Market Cap
$63.14 million
Optionable
Optionable
Beta
0.28

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:IMMX) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners